nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—CYP1A2—Anastrozole—breast cancer	0.0717	0.401	CbGbCtD
Pentoxifylline—CYP1A2—Toremifene—breast cancer	0.0656	0.367	CbGbCtD
Pentoxifylline—CYP1A2—Tamoxifen—breast cancer	0.024	0.134	CbGbCtD
Pentoxifylline—CYP1A2—Fluorouracil—breast cancer	0.0177	0.0987	CbGbCtD
Pentoxifylline—NT5E—mammary gland—breast cancer	0.0077	0.0623	CbGeAlD
Pentoxifylline—PDE4A—mammary gland—breast cancer	0.00588	0.0476	CbGeAlD
Pentoxifylline—ADORA2B—nipple—breast cancer	0.00545	0.0441	CbGeAlD
Pentoxifylline—NT5E—embryo—breast cancer	0.00525	0.0425	CbGeAlD
Pentoxifylline—NT5E—epithelium—breast cancer	0.00429	0.0347	CbGeAlD
Pentoxifylline—NT5E—skin of body—breast cancer	0.00408	0.033	CbGeAlD
Pentoxifylline—NT5E—endometrium—breast cancer	0.00385	0.0311	CbGeAlD
Pentoxifylline—NT5E—uterus—breast cancer	0.00354	0.0287	CbGeAlD
Pentoxifylline—NT5E—pituitary gland—breast cancer	0.00348	0.0282	CbGeAlD
Pentoxifylline—NT5E—adipose tissue—breast cancer	0.00347	0.028	CbGeAlD
Pentoxifylline—NT5E—female reproductive system—breast cancer	0.00319	0.0258	CbGeAlD
Pentoxifylline—NT5E—adrenal gland—breast cancer	0.00311	0.0252	CbGeAlD
Pentoxifylline—NT5E—bone marrow—breast cancer	0.00301	0.0243	CbGeAlD
Pentoxifylline—ADORA2B—pituitary gland—breast cancer	0.00298	0.0241	CbGeAlD
Pentoxifylline—ADORA2B—adipose tissue—breast cancer	0.00297	0.024	CbGeAlD
Pentoxifylline—NT5E—female gonad—breast cancer	0.0029	0.0235	CbGeAlD
Pentoxifylline—PDE4B—nipple—breast cancer	0.0029	0.0235	CbGeAlD
Pentoxifylline—PDE5A—epithelium—breast cancer	0.00278	0.0225	CbGeAlD
Pentoxifylline—NT5E—endocrine gland—breast cancer	0.0027	0.0218	CbGeAlD
Pentoxifylline—PDE4A—adipose tissue—breast cancer	0.00264	0.0214	CbGeAlD
Pentoxifylline—Caffeine—ATM—breast cancer	0.00249	0.202	CrCbGaD
Pentoxifylline—PDE4A—adrenal gland—breast cancer	0.00237	0.0192	CbGeAlD
Pentoxifylline—Caffeine—PIK3CB—breast cancer	0.00228	0.185	CrCbGaD
Pentoxifylline—Caffeine—PIK3CD—breast cancer	0.00228	0.185	CrCbGaD
Pentoxifylline—ADORA2A—female reproductive system—breast cancer	0.00227	0.0184	CbGeAlD
Pentoxifylline—PDE5A—adipose tissue—breast cancer	0.00225	0.0182	CbGeAlD
Pentoxifylline—ADORA2A—adrenal gland—breast cancer	0.00221	0.0179	CbGeAlD
Pentoxifylline—PDE4A—female gonad—breast cancer	0.00221	0.0179	CbGeAlD
Pentoxifylline—ADORA1—adipose tissue—breast cancer	0.00213	0.0173	CbGeAlD
Pentoxifylline—PDE5A—female reproductive system—breast cancer	0.00207	0.0167	CbGeAlD
Pentoxifylline—PDE5A—adrenal gland—breast cancer	0.00202	0.0163	CbGeAlD
Pentoxifylline—ADORA1—female reproductive system—breast cancer	0.00196	0.0159	CbGeAlD
Pentoxifylline—ADORA2A—endocrine gland—breast cancer	0.00192	0.0155	CbGeAlD
Pentoxifylline—PDE5A—female gonad—breast cancer	0.00188	0.0152	CbGeAlD
Pentoxifylline—NT5E—lymph node—breast cancer	0.00186	0.0151	CbGeAlD
Pentoxifylline—CYP1A2—nipple—breast cancer	0.00178	0.0144	CbGeAlD
Pentoxifylline—Caffeine—PIK3CA—breast cancer	0.00176	0.143	CrCbGaD
Pentoxifylline—PDE4B—endometrium—breast cancer	0.00175	0.0142	CbGeAlD
Pentoxifylline—PDE5A—endocrine gland—breast cancer	0.00175	0.0142	CbGeAlD
Pentoxifylline—ADORA1—endocrine gland—breast cancer	0.00166	0.0134	CbGeAlD
Pentoxifylline—Dyphylline—PDE4D—breast cancer	0.00165	0.134	CrCbGaD
Pentoxifylline—PDE4B—pituitary gland—breast cancer	0.00158	0.0128	CbGeAlD
Pentoxifylline—PDE4B—adipose tissue—breast cancer	0.00158	0.0128	CbGeAlD
Pentoxifylline—PDE4B—female reproductive system—breast cancer	0.00145	0.0117	CbGeAlD
Pentoxifylline—PDE4A—lymph node—breast cancer	0.00142	0.0115	CbGeAlD
Pentoxifylline—PDE4B—adrenal gland—breast cancer	0.00141	0.0114	CbGeAlD
Pentoxifylline—PDE4B—bone marrow—breast cancer	0.00137	0.0111	CbGeAlD
Pentoxifylline—PDE4B—female gonad—breast cancer	0.00132	0.0107	CbGeAlD
Pentoxifylline—PDE4B—endocrine gland—breast cancer	0.00123	0.00993	CbGeAlD
Pentoxifylline—PDE5A—lymph node—breast cancer	0.00121	0.00979	CbGeAlD
Pentoxifylline—ADORA1—lymph node—breast cancer	0.00115	0.00928	CbGeAlD
Pentoxifylline—PDE4B—lymph node—breast cancer	0.000848	0.00686	CbGeAlD
Pentoxifylline—CYP1A2—endocrine gland—breast cancer	0.000753	0.0061	CbGeAlD
Pentoxifylline—Caffeine—CYP1B1—breast cancer	0.000717	0.0583	CrCbGaD
Pentoxifylline—Caffeine—CYP1A1—breast cancer	0.000387	0.0315	CrCbGaD
Pentoxifylline—Caffeine—CYP2D6—breast cancer	0.000288	0.0234	CrCbGaD
Pentoxifylline—Caffeine—CYP3A4—breast cancer	0.000247	0.0201	CrCbGaD
Pentoxifylline—Caffeine—ABCB1—breast cancer	0.000206	0.0167	CrCbGaD
Pentoxifylline—Hepatitis—Epirubicin—breast cancer	0.000133	0.000328	CcSEcCtD
Pentoxifylline—Diarrhoea—Fluorouracil—breast cancer	0.000132	0.000328	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Capecitabine—breast cancer	0.000132	0.000328	CcSEcCtD
Pentoxifylline—Tachycardia—Capecitabine—breast cancer	0.000132	0.000327	CcSEcCtD
Pentoxifylline—Skin disorder—Capecitabine—breast cancer	0.000131	0.000325	CcSEcCtD
Pentoxifylline—Sweating—Doxorubicin—breast cancer	0.000131	0.000324	CcSEcCtD
Pentoxifylline—Urticaria—Paclitaxel—breast cancer	0.000131	0.000324	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Capecitabine—breast cancer	0.000131	0.000324	CcSEcCtD
Pentoxifylline—Hypotension—Docetaxel—breast cancer	0.00013	0.000323	CcSEcCtD
Pentoxifylline—Body temperature increased—Paclitaxel—breast cancer	0.00013	0.000323	CcSEcCtD
Pentoxifylline—Abdominal pain—Paclitaxel—breast cancer	0.00013	0.000323	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Doxorubicin—breast cancer	0.000129	0.00032	CcSEcCtD
Pentoxifylline—Epistaxis—Doxorubicin—breast cancer	0.000129	0.000319	CcSEcCtD
Pentoxifylline—Anorexia—Capecitabine—breast cancer	0.000129	0.000319	CcSEcCtD
Pentoxifylline—Vomiting—Mitoxantrone—breast cancer	0.000128	0.000318	CcSEcCtD
Pentoxifylline—Vomiting—Irinotecan—breast cancer	0.000128	0.000318	CcSEcCtD
Pentoxifylline—Immune system disorder—Methotrexate—breast cancer	0.000128	0.000317	CcSEcCtD
Pentoxifylline—Dizziness—Fluorouracil—breast cancer	0.000128	0.000317	CcSEcCtD
Pentoxifylline—Rash—Irinotecan—breast cancer	0.000127	0.000315	CcSEcCtD
Pentoxifylline—Rash—Mitoxantrone—breast cancer	0.000127	0.000315	CcSEcCtD
Pentoxifylline—Dermatitis—Mitoxantrone—breast cancer	0.000127	0.000315	CcSEcCtD
Pentoxifylline—Dermatitis—Irinotecan—breast cancer	0.000127	0.000315	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000127	0.000315	CcSEcCtD
Pentoxifylline—Headache—Irinotecan—breast cancer	0.000127	0.000313	CcSEcCtD
Pentoxifylline—Headache—Mitoxantrone—breast cancer	0.000127	0.000313	CcSEcCtD
Pentoxifylline—Hypotension—Capecitabine—breast cancer	0.000126	0.000313	CcSEcCtD
Pentoxifylline—Insomnia—Docetaxel—breast cancer	0.000126	0.000313	CcSEcCtD
Pentoxifylline—Vomiting—Gemcitabine—breast cancer	0.000125	0.00031	CcSEcCtD
Pentoxifylline—Dyspnoea—Docetaxel—breast cancer	0.000124	0.000308	CcSEcCtD
Pentoxifylline—Somnolence—Docetaxel—breast cancer	0.000124	0.000307	CcSEcCtD
Pentoxifylline—Rash—Gemcitabine—breast cancer	0.000124	0.000307	CcSEcCtD
Pentoxifylline—Dermatitis—Gemcitabine—breast cancer	0.000124	0.000307	CcSEcCtD
Pentoxifylline—Erythema—Methotrexate—breast cancer	0.000123	0.000305	CcSEcCtD
Pentoxifylline—Haemoglobin—Doxorubicin—breast cancer	0.000123	0.000305	CcSEcCtD
Pentoxifylline—Headache—Gemcitabine—breast cancer	0.000123	0.000305	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000123	0.000305	CcSEcCtD
Pentoxifylline—Flushing—Epirubicin—breast cancer	0.000123	0.000305	CcSEcCtD
Pentoxifylline—Vomiting—Fluorouracil—breast cancer	0.000123	0.000305	CcSEcCtD
Pentoxifylline—Dyspepsia—Docetaxel—breast cancer	0.000123	0.000304	CcSEcCtD
Pentoxifylline—Haemorrhage—Doxorubicin—breast cancer	0.000123	0.000304	CcSEcCtD
Pentoxifylline—Hepatitis—Doxorubicin—breast cancer	0.000123	0.000304	CcSEcCtD
Pentoxifylline—Insomnia—Capecitabine—breast cancer	0.000122	0.000303	CcSEcCtD
Pentoxifylline—Rash—Fluorouracil—breast cancer	0.000122	0.000302	CcSEcCtD
Pentoxifylline—Dermatitis—Fluorouracil—breast cancer	0.000122	0.000302	CcSEcCtD
Pentoxifylline—Decreased appetite—Docetaxel—breast cancer	0.000121	0.000301	CcSEcCtD
Pentoxifylline—Hypersensitivity—Paclitaxel—breast cancer	0.000121	0.000301	CcSEcCtD
Pentoxifylline—Headache—Fluorouracil—breast cancer	0.000121	0.0003	CcSEcCtD
Pentoxifylline—Dysgeusia—Methotrexate—breast cancer	0.000121	0.000299	CcSEcCtD
Pentoxifylline—Dyspnoea—Capecitabine—breast cancer	0.00012	0.000299	CcSEcCtD
Pentoxifylline—Nausea—Mitoxantrone—breast cancer	0.00012	0.000297	CcSEcCtD
Pentoxifylline—Nausea—Irinotecan—breast cancer	0.00012	0.000297	CcSEcCtD
Pentoxifylline—Immune system disorder—Epirubicin—breast cancer	0.00012	0.000297	CcSEcCtD
Pentoxifylline—Constipation—Docetaxel—breast cancer	0.000119	0.000296	CcSEcCtD
Pentoxifylline—Back pain—Methotrexate—breast cancer	0.000119	0.000295	CcSEcCtD
Pentoxifylline—Dyspepsia—Capecitabine—breast cancer	0.000119	0.000295	CcSEcCtD
Pentoxifylline—Arrhythmia—Epirubicin—breast cancer	0.000118	0.000293	CcSEcCtD
Pentoxifylline—Asthenia—Paclitaxel—breast cancer	0.000118	0.000293	CcSEcCtD
Pentoxifylline—Decreased appetite—Capecitabine—breast cancer	0.000117	0.000291	CcSEcCtD
Pentoxifylline—Nausea—Gemcitabine—breast cancer	0.000117	0.000289	CcSEcCtD
Pentoxifylline—Pruritus—Paclitaxel—breast cancer	0.000117	0.000289	CcSEcCtD
Pentoxifylline—Vision blurred—Methotrexate—breast cancer	0.000116	0.000288	CcSEcCtD
Pentoxifylline—Constipation—Capecitabine—breast cancer	0.000116	0.000286	CcSEcCtD
Pentoxifylline—Erythema—Epirubicin—breast cancer	0.000115	0.000286	CcSEcCtD
Pentoxifylline—Feeling abnormal—Docetaxel—breast cancer	0.000115	0.000285	CcSEcCtD
Pentoxifylline—Nausea—Fluorouracil—breast cancer	0.000115	0.000285	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Methotrexate—breast cancer	0.000114	0.000283	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Docetaxel—breast cancer	0.000114	0.000283	CcSEcCtD
Pentoxifylline—Anaemia—Methotrexate—breast cancer	0.000114	0.000282	CcSEcCtD
Pentoxifylline—Flushing—Doxorubicin—breast cancer	0.000114	0.000282	CcSEcCtD
Pentoxifylline—Flatulence—Epirubicin—breast cancer	0.000114	0.000282	CcSEcCtD
Pentoxifylline—Tension—Epirubicin—breast cancer	0.000113	0.00028	CcSEcCtD
Pentoxifylline—Dysgeusia—Epirubicin—breast cancer	0.000113	0.00028	CcSEcCtD
Pentoxifylline—Diarrhoea—Paclitaxel—breast cancer	0.000113	0.000279	CcSEcCtD
Pentoxifylline—Nervousness—Epirubicin—breast cancer	0.000112	0.000278	CcSEcCtD
Pentoxifylline—Back pain—Epirubicin—breast cancer	0.000112	0.000276	CcSEcCtD
Pentoxifylline—Feeling abnormal—Capecitabine—breast cancer	0.000111	0.000276	CcSEcCtD
Pentoxifylline—Malaise—Methotrexate—breast cancer	0.000111	0.000275	CcSEcCtD
Pentoxifylline—Muscle spasms—Epirubicin—breast cancer	0.000111	0.000275	CcSEcCtD
Pentoxifylline—Immune system disorder—Doxorubicin—breast cancer	0.000111	0.000274	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Capecitabine—breast cancer	0.000111	0.000274	CcSEcCtD
Pentoxifylline—Abdominal pain—Docetaxel—breast cancer	0.00011	0.000273	CcSEcCtD
Pentoxifylline—Body temperature increased—Docetaxel—breast cancer	0.00011	0.000273	CcSEcCtD
Pentoxifylline—Leukopenia—Methotrexate—breast cancer	0.00011	0.000273	CcSEcCtD
Pentoxifylline—Arrhythmia—Doxorubicin—breast cancer	0.00011	0.000271	CcSEcCtD
Pentoxifylline—Dizziness—Paclitaxel—breast cancer	0.000109	0.00027	CcSEcCtD
Pentoxifylline—Vision blurred—Epirubicin—breast cancer	0.000109	0.000269	CcSEcCtD
Pentoxifylline—Urticaria—Capecitabine—breast cancer	0.000107	0.000266	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Epirubicin—breast cancer	0.000107	0.000265	CcSEcCtD
Pentoxifylline—Abdominal pain—Capecitabine—breast cancer	0.000107	0.000265	CcSEcCtD
Pentoxifylline—Body temperature increased—Capecitabine—breast cancer	0.000107	0.000265	CcSEcCtD
Pentoxifylline—Convulsion—Methotrexate—breast cancer	0.000107	0.000265	CcSEcCtD
Pentoxifylline—Erythema—Doxorubicin—breast cancer	0.000107	0.000264	CcSEcCtD
Pentoxifylline—Anaemia—Epirubicin—breast cancer	0.000107	0.000264	CcSEcCtD
Pentoxifylline—Agitation—Epirubicin—breast cancer	0.000106	0.000263	CcSEcCtD
Pentoxifylline—Flatulence—Doxorubicin—breast cancer	0.000105	0.000261	CcSEcCtD
Pentoxifylline—Chest pain—Methotrexate—breast cancer	0.000105	0.00026	CcSEcCtD
Pentoxifylline—Myalgia—Methotrexate—breast cancer	0.000105	0.00026	CcSEcCtD
Pentoxifylline—Tension—Doxorubicin—breast cancer	0.000105	0.00026	CcSEcCtD
Pentoxifylline—Vomiting—Paclitaxel—breast cancer	0.000105	0.000259	CcSEcCtD
Pentoxifylline—Dysgeusia—Doxorubicin—breast cancer	0.000105	0.000259	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000104	0.000258	CcSEcCtD
Pentoxifylline—Malaise—Epirubicin—breast cancer	0.000104	0.000258	CcSEcCtD
Pentoxifylline—Rash—Paclitaxel—breast cancer	0.000104	0.000257	CcSEcCtD
Pentoxifylline—Dermatitis—Paclitaxel—breast cancer	0.000104	0.000257	CcSEcCtD
Pentoxifylline—Discomfort—Methotrexate—breast cancer	0.000104	0.000257	CcSEcCtD
Pentoxifylline—Nervousness—Doxorubicin—breast cancer	0.000104	0.000257	CcSEcCtD
Pentoxifylline—Leukopenia—Epirubicin—breast cancer	0.000103	0.000256	CcSEcCtD
Pentoxifylline—Back pain—Doxorubicin—breast cancer	0.000103	0.000256	CcSEcCtD
Pentoxifylline—Headache—Paclitaxel—breast cancer	0.000103	0.000256	CcSEcCtD
Pentoxifylline—Hypersensitivity—Docetaxel—breast cancer	0.000103	0.000255	CcSEcCtD
Pentoxifylline—Muscle spasms—Doxorubicin—breast cancer	0.000103	0.000254	CcSEcCtD
Pentoxifylline—Palpitations—Epirubicin—breast cancer	0.000102	0.000253	CcSEcCtD
Pentoxifylline—Confusional state—Methotrexate—breast cancer	0.000101	0.000251	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Methotrexate—breast cancer	0.000101	0.000249	CcSEcCtD
Pentoxifylline—Vision blurred—Doxorubicin—breast cancer	0.000101	0.000249	CcSEcCtD
Pentoxifylline—Asthenia—Docetaxel—breast cancer	0.0001	0.000248	CcSEcCtD
Pentoxifylline—Convulsion—Epirubicin—breast cancer	0.0001	0.000248	CcSEcCtD
Pentoxifylline—Infection—Methotrexate—breast cancer	0.0001	0.000248	CcSEcCtD
Pentoxifylline—Hypertension—Epirubicin—breast cancer	9.96e-05	0.000247	CcSEcCtD
Pentoxifylline—Hypersensitivity—Capecitabine—breast cancer	9.96e-05	0.000247	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Doxorubicin—breast cancer	9.9e-05	0.000245	CcSEcCtD
Pentoxifylline—Pruritus—Docetaxel—breast cancer	9.88e-05	0.000245	CcSEcCtD
Pentoxifylline—Anaemia—Doxorubicin—breast cancer	9.87e-05	0.000244	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Methotrexate—breast cancer	9.85e-05	0.000244	CcSEcCtD
Pentoxifylline—Chest pain—Epirubicin—breast cancer	9.82e-05	0.000243	CcSEcCtD
Pentoxifylline—Myalgia—Epirubicin—breast cancer	9.82e-05	0.000243	CcSEcCtD
Pentoxifylline—Agitation—Doxorubicin—breast cancer	9.81e-05	0.000243	CcSEcCtD
Pentoxifylline—Anxiety—Epirubicin—breast cancer	9.79e-05	0.000242	CcSEcCtD
Pentoxifylline—Nausea—Paclitaxel—breast cancer	9.78e-05	0.000242	CcSEcCtD
Pentoxifylline—Skin disorder—Methotrexate—breast cancer	9.77e-05	0.000242	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	9.75e-05	0.000242	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Methotrexate—breast cancer	9.73e-05	0.000241	CcSEcCtD
Pentoxifylline—Discomfort—Epirubicin—breast cancer	9.7e-05	0.00024	CcSEcCtD
Pentoxifylline—Asthenia—Capecitabine—breast cancer	9.7e-05	0.00024	CcSEcCtD
Pentoxifylline—Malaise—Doxorubicin—breast cancer	9.63e-05	0.000238	CcSEcCtD
Pentoxifylline—Dry mouth—Epirubicin—breast cancer	9.61e-05	0.000238	CcSEcCtD
Pentoxifylline—Anorexia—Methotrexate—breast cancer	9.59e-05	0.000238	CcSEcCtD
Pentoxifylline—Pruritus—Capecitabine—breast cancer	9.56e-05	0.000237	CcSEcCtD
Pentoxifylline—Leukopenia—Doxorubicin—breast cancer	9.56e-05	0.000237	CcSEcCtD
Pentoxifylline—Diarrhoea—Docetaxel—breast cancer	9.55e-05	0.000237	CcSEcCtD
Pentoxifylline—Confusional state—Epirubicin—breast cancer	9.49e-05	0.000235	CcSEcCtD
Pentoxifylline—Palpitations—Doxorubicin—breast cancer	9.43e-05	0.000234	CcSEcCtD
Pentoxifylline—Oedema—Epirubicin—breast cancer	9.42e-05	0.000233	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Epirubicin—breast cancer	9.42e-05	0.000233	CcSEcCtD
Pentoxifylline—Hypotension—Methotrexate—breast cancer	9.4e-05	0.000233	CcSEcCtD
Pentoxifylline—Infection—Epirubicin—breast cancer	9.35e-05	0.000232	CcSEcCtD
Pentoxifylline—Shock—Epirubicin—breast cancer	9.26e-05	0.000229	CcSEcCtD
Pentoxifylline—Convulsion—Doxorubicin—breast cancer	9.25e-05	0.000229	CcSEcCtD
Pentoxifylline—Diarrhoea—Capecitabine—breast cancer	9.25e-05	0.000229	CcSEcCtD
Pentoxifylline—Dizziness—Docetaxel—breast cancer	9.23e-05	0.000229	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Epirubicin—breast cancer	9.22e-05	0.000228	CcSEcCtD
Pentoxifylline—Hypertension—Doxorubicin—breast cancer	9.22e-05	0.000228	CcSEcCtD
Pentoxifylline—Tachycardia—Epirubicin—breast cancer	9.19e-05	0.000228	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Methotrexate—breast cancer	9.17e-05	0.000227	CcSEcCtD
Pentoxifylline—Skin disorder—Epirubicin—breast cancer	9.15e-05	0.000227	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Epirubicin—breast cancer	9.1e-05	0.000225	CcSEcCtD
Pentoxifylline—Insomnia—Methotrexate—breast cancer	9.1e-05	0.000225	CcSEcCtD
Pentoxifylline—Chest pain—Doxorubicin—breast cancer	9.09e-05	0.000225	CcSEcCtD
Pentoxifylline—Myalgia—Doxorubicin—breast cancer	9.09e-05	0.000225	CcSEcCtD
Pentoxifylline—Anxiety—Doxorubicin—breast cancer	9.06e-05	0.000224	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.03e-05	0.000224	CcSEcCtD
Pentoxifylline—Discomfort—Doxorubicin—breast cancer	8.98e-05	0.000222	CcSEcCtD
Pentoxifylline—Anorexia—Epirubicin—breast cancer	8.98e-05	0.000222	CcSEcCtD
Pentoxifylline—Dyspnoea—Methotrexate—breast cancer	8.97e-05	0.000222	CcSEcCtD
Pentoxifylline—Somnolence—Methotrexate—breast cancer	8.94e-05	0.000222	CcSEcCtD
Pentoxifylline—Dizziness—Capecitabine—breast cancer	8.94e-05	0.000221	CcSEcCtD
Pentoxifylline—Dry mouth—Doxorubicin—breast cancer	8.89e-05	0.00022	CcSEcCtD
Pentoxifylline—Vomiting—Docetaxel—breast cancer	8.88e-05	0.00022	CcSEcCtD
Pentoxifylline—Dyspepsia—Methotrexate—breast cancer	8.86e-05	0.000219	CcSEcCtD
Pentoxifylline—Rash—Docetaxel—breast cancer	8.8e-05	0.000218	CcSEcCtD
Pentoxifylline—Hypotension—Epirubicin—breast cancer	8.8e-05	0.000218	CcSEcCtD
Pentoxifylline—Dermatitis—Docetaxel—breast cancer	8.79e-05	0.000218	CcSEcCtD
Pentoxifylline—Confusional state—Doxorubicin—breast cancer	8.78e-05	0.000218	CcSEcCtD
Pentoxifylline—Decreased appetite—Methotrexate—breast cancer	8.75e-05	0.000217	CcSEcCtD
Pentoxifylline—Headache—Docetaxel—breast cancer	8.75e-05	0.000217	CcSEcCtD
Pentoxifylline—Oedema—Doxorubicin—breast cancer	8.71e-05	0.000216	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Doxorubicin—breast cancer	8.71e-05	0.000216	CcSEcCtD
Pentoxifylline—Infection—Doxorubicin—breast cancer	8.66e-05	0.000214	CcSEcCtD
Pentoxifylline—Vomiting—Capecitabine—breast cancer	8.59e-05	0.000213	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Epirubicin—breast cancer	8.58e-05	0.000213	CcSEcCtD
Pentoxifylline—Shock—Doxorubicin—breast cancer	8.57e-05	0.000212	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Doxorubicin—breast cancer	8.53e-05	0.000211	CcSEcCtD
Pentoxifylline—Rash—Capecitabine—breast cancer	8.52e-05	0.000211	CcSEcCtD
Pentoxifylline—Insomnia—Epirubicin—breast cancer	8.52e-05	0.000211	CcSEcCtD
Pentoxifylline—Dermatitis—Capecitabine—breast cancer	8.51e-05	0.000211	CcSEcCtD
Pentoxifylline—Tachycardia—Doxorubicin—breast cancer	8.5e-05	0.000211	CcSEcCtD
Pentoxifylline—Headache—Capecitabine—breast cancer	8.47e-05	0.00021	CcSEcCtD
Pentoxifylline—Skin disorder—Doxorubicin—breast cancer	8.46e-05	0.00021	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Doxorubicin—breast cancer	8.42e-05	0.000209	CcSEcCtD
Pentoxifylline—Dyspnoea—Epirubicin—breast cancer	8.39e-05	0.000208	CcSEcCtD
Pentoxifylline—Somnolence—Epirubicin—breast cancer	8.37e-05	0.000207	CcSEcCtD
Pentoxifylline—Anorexia—Doxorubicin—breast cancer	8.3e-05	0.000206	CcSEcCtD
Pentoxifylline—Nausea—Docetaxel—breast cancer	8.29e-05	0.000205	CcSEcCtD
Pentoxifylline—Feeling abnormal—Methotrexate—breast cancer	8.29e-05	0.000205	CcSEcCtD
Pentoxifylline—Dyspepsia—Epirubicin—breast cancer	8.29e-05	0.000205	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Methotrexate—breast cancer	8.23e-05	0.000204	CcSEcCtD
Pentoxifylline—Decreased appetite—Epirubicin—breast cancer	8.18e-05	0.000203	CcSEcCtD
Pentoxifylline—Hypotension—Doxorubicin—breast cancer	8.14e-05	0.000202	CcSEcCtD
Pentoxifylline—Constipation—Epirubicin—breast cancer	8.05e-05	0.000199	CcSEcCtD
Pentoxifylline—Nausea—Capecitabine—breast cancer	8.03e-05	0.000199	CcSEcCtD
Pentoxifylline—Urticaria—Methotrexate—breast cancer	7.99e-05	0.000198	CcSEcCtD
Pentoxifylline—Body temperature increased—Methotrexate—breast cancer	7.95e-05	0.000197	CcSEcCtD
Pentoxifylline—Abdominal pain—Methotrexate—breast cancer	7.95e-05	0.000197	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.94e-05	0.000197	CcSEcCtD
Pentoxifylline—Insomnia—Doxorubicin—breast cancer	7.88e-05	0.000195	CcSEcCtD
Pentoxifylline—Dyspnoea—Doxorubicin—breast cancer	7.77e-05	0.000192	CcSEcCtD
Pentoxifylline—Feeling abnormal—Epirubicin—breast cancer	7.76e-05	0.000192	CcSEcCtD
Pentoxifylline—Somnolence—Doxorubicin—breast cancer	7.75e-05	0.000192	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Epirubicin—breast cancer	7.7e-05	0.000191	CcSEcCtD
Pentoxifylline—Dyspepsia—Doxorubicin—breast cancer	7.67e-05	0.00019	CcSEcCtD
Pentoxifylline—Decreased appetite—Doxorubicin—breast cancer	7.57e-05	0.000188	CcSEcCtD
Pentoxifylline—Urticaria—Epirubicin—breast cancer	7.48e-05	0.000185	CcSEcCtD
Pentoxifylline—Constipation—Doxorubicin—breast cancer	7.45e-05	0.000185	CcSEcCtD
Pentoxifylline—Abdominal pain—Epirubicin—breast cancer	7.44e-05	0.000184	CcSEcCtD
Pentoxifylline—Body temperature increased—Epirubicin—breast cancer	7.44e-05	0.000184	CcSEcCtD
Pentoxifylline—Hypersensitivity—Methotrexate—breast cancer	7.41e-05	0.000184	CcSEcCtD
Pentoxifylline—Asthenia—Methotrexate—breast cancer	7.22e-05	0.000179	CcSEcCtD
Pentoxifylline—Feeling abnormal—Doxorubicin—breast cancer	7.18e-05	0.000178	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Doxorubicin—breast cancer	7.12e-05	0.000176	CcSEcCtD
Pentoxifylline—Pruritus—Methotrexate—breast cancer	7.12e-05	0.000176	CcSEcCtD
Pentoxifylline—Hypersensitivity—Epirubicin—breast cancer	6.94e-05	0.000172	CcSEcCtD
Pentoxifylline—Urticaria—Doxorubicin—breast cancer	6.92e-05	0.000171	CcSEcCtD
Pentoxifylline—Abdominal pain—Doxorubicin—breast cancer	6.89e-05	0.000171	CcSEcCtD
Pentoxifylline—Body temperature increased—Doxorubicin—breast cancer	6.89e-05	0.000171	CcSEcCtD
Pentoxifylline—Diarrhoea—Methotrexate—breast cancer	6.88e-05	0.000171	CcSEcCtD
Pentoxifylline—Asthenia—Epirubicin—breast cancer	6.76e-05	0.000167	CcSEcCtD
Pentoxifylline—Pruritus—Epirubicin—breast cancer	6.66e-05	0.000165	CcSEcCtD
Pentoxifylline—Dizziness—Methotrexate—breast cancer	6.65e-05	0.000165	CcSEcCtD
Pentoxifylline—Diarrhoea—Epirubicin—breast cancer	6.44e-05	0.00016	CcSEcCtD
Pentoxifylline—Hypersensitivity—Doxorubicin—breast cancer	6.42e-05	0.000159	CcSEcCtD
Pentoxifylline—Vomiting—Methotrexate—breast cancer	6.4e-05	0.000158	CcSEcCtD
Pentoxifylline—Rash—Methotrexate—breast cancer	6.34e-05	0.000157	CcSEcCtD
Pentoxifylline—Dermatitis—Methotrexate—breast cancer	6.34e-05	0.000157	CcSEcCtD
Pentoxifylline—Headache—Methotrexate—breast cancer	6.3e-05	0.000156	CcSEcCtD
Pentoxifylline—Asthenia—Doxorubicin—breast cancer	6.25e-05	0.000155	CcSEcCtD
Pentoxifylline—Dizziness—Epirubicin—breast cancer	6.23e-05	0.000154	CcSEcCtD
Pentoxifylline—Pruritus—Doxorubicin—breast cancer	6.16e-05	0.000153	CcSEcCtD
Pentoxifylline—Vomiting—Epirubicin—breast cancer	5.99e-05	0.000148	CcSEcCtD
Pentoxifylline—Nausea—Methotrexate—breast cancer	5.98e-05	0.000148	CcSEcCtD
Pentoxifylline—Diarrhoea—Doxorubicin—breast cancer	5.96e-05	0.000148	CcSEcCtD
Pentoxifylline—Rash—Epirubicin—breast cancer	5.94e-05	0.000147	CcSEcCtD
Pentoxifylline—Dermatitis—Epirubicin—breast cancer	5.93e-05	0.000147	CcSEcCtD
Pentoxifylline—Headache—Epirubicin—breast cancer	5.9e-05	0.000146	CcSEcCtD
Pentoxifylline—Dizziness—Doxorubicin—breast cancer	5.76e-05	0.000143	CcSEcCtD
Pentoxifylline—Nausea—Epirubicin—breast cancer	5.59e-05	0.000139	CcSEcCtD
Pentoxifylline—Vomiting—Doxorubicin—breast cancer	5.54e-05	0.000137	CcSEcCtD
Pentoxifylline—Rash—Doxorubicin—breast cancer	5.49e-05	0.000136	CcSEcCtD
Pentoxifylline—Dermatitis—Doxorubicin—breast cancer	5.49e-05	0.000136	CcSEcCtD
Pentoxifylline—Headache—Doxorubicin—breast cancer	5.46e-05	0.000135	CcSEcCtD
Pentoxifylline—Nausea—Doxorubicin—breast cancer	5.17e-05	0.000128	CcSEcCtD
Pentoxifylline—CYP1A2—Metabolism—GSTA3—breast cancer	1.33e-05	4.71e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMMR—breast cancer	1.33e-05	4.71e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NOS3—breast cancer	1.32e-05	4.7e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MTOR—breast cancer	1.32e-05	4.69e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CB—breast cancer	1.32e-05	4.69e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ESR1—breast cancer	1.32e-05	4.68e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCND1—breast cancer	1.3e-05	4.62e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FN1—breast cancer	1.3e-05	4.62e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—JUN—breast cancer	1.3e-05	4.61e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CTNNB1—breast cancer	1.29e-05	4.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NFKBIA—breast cancer	1.29e-05	4.57e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARGC1B—breast cancer	1.28e-05	4.56e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PIK3CA—breast cancer	1.28e-05	4.53e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOTCH1—breast cancer	1.27e-05	4.52e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MDM2—breast cancer	1.27e-05	4.51e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL8—breast cancer	1.27e-05	4.51e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RAF1—breast cancer	1.27e-05	4.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—breast cancer	1.26e-05	4.49e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RELA—breast cancer	1.26e-05	4.48e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—PIK3CA—breast cancer	1.26e-05	4.48e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—HRAS—breast cancer	1.26e-05	4.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CDKN1A—breast cancer	1.26e-05	4.47e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTEN—breast cancer	1.26e-05	4.46e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MDM2—breast cancer	1.26e-05	4.46e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ERBB2—breast cancer	1.25e-05	4.45e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RAF1—breast cancer	1.25e-05	4.44e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	1.25e-05	4.44e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	1.25e-05	4.44e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CG—breast cancer	1.25e-05	4.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KIT—breast cancer	1.25e-05	4.42e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RELA—breast cancer	1.25e-05	4.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APC—breast cancer	1.25e-05	4.42e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1B—breast cancer	1.24e-05	4.4e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ERBB2—breast cancer	1.24e-05	4.4e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CB—breast cancer	1.24e-05	4.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MTOR—breast cancer	1.24e-05	4.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGF—breast cancer	1.23e-05	4.37e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK8—breast cancer	1.23e-05	4.36e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—AKT1—breast cancer	1.23e-05	4.35e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—AKT1—breast cancer	1.23e-05	4.35e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MTOR—breast cancer	1.22e-05	4.34e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CB—breast cancer	1.22e-05	4.34e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CASP3—breast cancer	1.21e-05	4.31e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CA9—breast cancer	1.21e-05	4.31e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA4—breast cancer	1.21e-05	4.31e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL2—breast cancer	1.21e-05	4.31e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—breast cancer	1.21e-05	4.28e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—breast cancer	1.2e-05	4.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—MAPK3—breast cancer	1.19e-05	4.24e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL8—breast cancer	1.19e-05	4.22e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	1.18e-05	4.21e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCND1—breast cancer	1.18e-05	4.2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA2—breast cancer	1.18e-05	4.2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX2—breast cancer	1.18e-05	4.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—HRAS—breast cancer	1.18e-05	4.19e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—JUN—breast cancer	1.18e-05	4.19e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL8—breast cancer	1.17e-05	4.17e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—BRAF—breast cancer	1.17e-05	4.16e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CTNNB1—breast cancer	1.17e-05	4.16e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX4—breast cancer	1.17e-05	4.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SULT1A1—breast cancer	1.17e-05	4.15e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—HRAS—breast cancer	1.17e-05	4.14e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SRC—breast cancer	1.16e-05	4.14e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1B—breast cancer	1.16e-05	4.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—AKT1—breast cancer	1.15e-05	4.08e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—breast cancer	1.15e-05	4.07e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1B—breast cancer	1.15e-05	4.07e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1A—breast cancer	1.14e-05	4.06e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTEN—breast cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—breast cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTA1—breast cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—IDH1—breast cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT2—breast cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CASP3—breast cancer	1.14e-05	4.04e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL2—breast cancer	1.13e-05	4.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—EGFR—breast cancer	1.13e-05	4.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—VEGFA—breast cancer	1.13e-05	4.03e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—AKT1—breast cancer	1.13e-05	4.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—breast cancer	1.13e-05	4.01e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAT2—breast cancer	1.13e-05	4e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STAT3—breast cancer	1.12e-05	3.99e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CASP3—breast cancer	1.12e-05	3.99e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL2—breast cancer	1.12e-05	3.98e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—breast cancer	1.12e-05	3.96e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK8—breast cancer	1.12e-05	3.96e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—AKT1—breast cancer	1.11e-05	3.95e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCND1—breast cancer	1.11e-05	3.93e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—JUN—breast cancer	1.1e-05	3.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CTNNB1—breast cancer	1.1e-05	3.89e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CD—breast cancer	1.09e-05	3.89e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCND1—breast cancer	1.09e-05	3.88e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—JUN—breast cancer	1.09e-05	3.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—PIK3CA—breast cancer	1.08e-05	3.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SERPINE1—breast cancer	1.08e-05	3.85e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CTNNB1—breast cancer	1.08e-05	3.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—breast cancer	1.07e-05	3.82e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK3—breast cancer	1.07e-05	3.81e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—KRAS—breast cancer	1.07e-05	3.81e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1A—breast cancer	1.07e-05	3.8e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTEN—breast cancer	1.07e-05	3.79e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—breast cancer	1.06e-05	3.77e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1A—breast cancer	1.06e-05	3.76e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SRC—breast cancer	1.06e-05	3.76e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTEN—breast cancer	1.06e-05	3.75e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK8—breast cancer	1.04e-05	3.71e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MYC—breast cancer	1.04e-05	3.71e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—AKT1—breast cancer	1.04e-05	3.7e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TGFB1—breast cancer	1.04e-05	3.7e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOS3—breast cancer	1.03e-05	3.67e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK8—breast cancer	1.03e-05	3.67e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—VEGFA—breast cancer	1.03e-05	3.66e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—AKT1—breast cancer	1.03e-05	3.66e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EGFR—breast cancer	1.02e-05	3.63e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STAT3—breast cancer	1.02e-05	3.62e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—breast cancer	1.02e-05	3.62e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SRC—breast cancer	9.9e-06	3.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MED12—breast cancer	9.88e-06	3.51e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—DPYD—breast cancer	9.88e-06	3.51e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3CA—breast cancer	9.85e-06	3.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MDM2—breast cancer	9.81e-06	3.48e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SRC—breast cancer	9.79e-06	3.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RAF1—breast cancer	9.77e-06	3.47e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK3—breast cancer	9.74e-06	3.46e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RELA—breast cancer	9.73e-06	3.46e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALDOA—breast cancer	9.73e-06	3.46e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ERBB2—breast cancer	9.67e-06	3.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—VEGFA—breast cancer	9.65e-06	3.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KRAS—breast cancer	9.64e-06	3.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STAT3—breast cancer	9.55e-06	3.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MTOR—breast cancer	9.54e-06	3.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CB—breast cancer	9.54e-06	3.39e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—VEGFA—breast cancer	9.53e-06	3.39e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MYC—breast cancer	9.48e-06	3.37e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TGFB1—breast cancer	9.45e-06	3.36e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA3—breast cancer	9.44e-06	3.35e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STAT3—breast cancer	9.44e-06	3.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC2A2—breast cancer	9.38e-06	3.33e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	9.28e-06	3.3e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EGFR—breast cancer	9.27e-06	3.29e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CPT1A—breast cancer	9.19e-06	3.26e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCG2—breast cancer	9.19e-06	3.26e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTR—breast cancer	9.19e-06	3.26e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL8—breast cancer	9.17e-06	3.26e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK3—breast cancer	9.12e-06	3.24e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—HRAS—breast cancer	9.11e-06	3.24e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK3—breast cancer	9.02e-06	3.2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HPGDS—breast cancer	9.01e-06	3.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1B—breast cancer	8.95e-06	3.18e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HBA1—breast cancer	8.95e-06	3.18e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MYC—breast cancer	8.87e-06	3.15e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CA—breast cancer	8.86e-06	3.15e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—AKT1—breast cancer	8.86e-06	3.15e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TGFB1—breast cancer	8.85e-06	3.14e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CASP3—breast cancer	8.78e-06	3.12e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MYC—breast cancer	8.77e-06	3.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL2—breast cancer	8.76e-06	3.11e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KRAS—breast cancer	8.76e-06	3.11e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TGFB1—breast cancer	8.75e-06	3.11e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTT1—breast cancer	8.74e-06	3.1e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ACHE—breast cancer	8.74e-06	3.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—breast cancer	8.72e-06	3.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EGFR—breast cancer	8.68e-06	3.08e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGFR—breast cancer	8.58e-06	3.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—breast cancer	8.57e-06	3.04e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCND1—breast cancer	8.54e-06	3.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—JUN—breast cancer	8.52e-06	3.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CTNNB1—breast cancer	8.46e-06	3.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—breast cancer	8.29e-06	2.95e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP17A1—breast cancer	8.27e-06	2.94e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1A—breast cancer	8.26e-06	2.94e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTEN—breast cancer	8.24e-06	2.93e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KRAS—breast cancer	8.2e-06	2.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—HRAS—breast cancer	8.2e-06	2.91e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS1—breast cancer	8.19e-06	2.91e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ENO1—breast cancer	8.19e-06	2.91e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	8.16e-06	2.9e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KRAS—breast cancer	8.1e-06	2.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK8—breast cancer	8.07e-06	2.87e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	8.05e-06	2.86e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CA—breast cancer	8.05e-06	2.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT1—breast cancer	8.04e-06	2.86e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2D6—breast cancer	8.03e-06	2.85e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA2—breast cancer	7.88e-06	2.8e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—breast cancer	7.85e-06	2.79e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—breast cancer	7.78e-06	2.76e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SRC—breast cancer	7.65e-06	2.72e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—FASN—breast cancer	7.64e-06	2.72e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—BCHE—breast cancer	7.61e-06	2.7e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CA—breast cancer	7.53e-06	2.68e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC5A5—breast cancer	7.52e-06	2.67e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—VEGFA—breast cancer	7.45e-06	2.65e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CA—breast cancer	7.44e-06	2.64e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—HRAS—breast cancer	7.44e-06	2.64e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STAT3—breast cancer	7.37e-06	2.62e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—breast cancer	7.29e-06	2.59e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NQO1—breast cancer	7.26e-06	2.58e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC2A1—breast cancer	7.26e-06	2.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT1—breast cancer	7.24e-06	2.57e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—breast cancer	7.2e-06	2.56e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—breast cancer	7.12e-06	2.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	7.11e-06	2.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP3A4—breast cancer	7.08e-06	2.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	7.05e-06	2.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK3—breast cancer	7.04e-06	2.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—HRAS—breast cancer	6.97e-06	2.48e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP1B1—breast cancer	6.96e-06	2.47e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—HRAS—breast cancer	6.89e-06	2.45e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MYC—breast cancer	6.85e-06	2.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFB1—breast cancer	6.84e-06	2.43e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSP90AA1—breast cancer	6.83e-06	2.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGFR—breast cancer	6.7e-06	2.38e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—breast cancer	6.67e-06	2.37e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA1—breast cancer	6.64e-06	2.36e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—breast cancer	6.59e-06	2.34e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT1—breast cancer	6.57e-06	2.33e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP19A1—breast cancer	6.55e-06	2.33e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—STK11—breast cancer	6.55e-06	2.33e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KRAS—breast cancer	6.33e-06	2.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT1—breast cancer	6.15e-06	2.19e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	6.14e-06	2.18e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—COMT—breast cancer	6.09e-06	2.16e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT1—breast cancer	6.08e-06	2.16e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTP1—breast cancer	6.06e-06	2.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMOX1—breast cancer	5.97e-06	2.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ITPR1—breast cancer	5.96e-06	2.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CA—breast cancer	5.82e-06	2.07e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCB1—breast cancer	5.73e-06	2.04e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—TYMS—breast cancer	5.63e-06	2e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—breast cancer	5.63e-06	2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOR1—breast cancer	5.57e-06	1.98e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLA2G4A—breast cancer	5.57e-06	1.98e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTM1—breast cancer	5.57e-06	1.98e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HRAS—breast cancer	5.38e-06	1.91e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX1—breast cancer	5.33e-06	1.89e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP1A1—breast cancer	5.28e-06	1.87e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ERCC2—breast cancer	5.23e-06	1.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—breast cancer	5.15e-06	1.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTHFR—breast cancer	4.92e-06	1.75e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT1—breast cancer	4.75e-06	1.69e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CAV1—breast cancer	4.54e-06	1.61e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.34e-06	1.54e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CG—breast cancer	4.13e-06	1.47e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CD—breast cancer	3.63e-06	1.29e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALB—breast cancer	3.59e-06	1.27e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NOS3—breast cancer	3.43e-06	1.22e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CB—breast cancer	3.17e-06	1.13e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—breast cancer	3.14e-06	1.11e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTEN—breast cancer	2.74e-06	9.72e-06	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CA—breast cancer	1.93e-06	6.86e-06	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKT1—breast cancer	1.58e-06	5.6e-06	CbGpPWpGaD
